Compare Abeona Therapeutics Inc (ABEO) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Yum China Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Yum China Holdings Inc trades at $42.83 (market cap $14.58B). The key difference: Yum China Holdings Inc is far larger — about 39.1× Abeona Therapeutics Inc's market cap, and Yum China Holdings Inc pays a 2.75% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | YUMC | |
|---|---|---|
Market Cap | $373.32M | $14.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $57.95 |
52-Week Low | $4.17 | $40.18 |
Enterprise Value | $228.22M | $15.47B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
YUMC trades at $42.22, up 1.25% today, with a bullish technical signal despite mixed moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.87 exceeding the $0.854 estimate. Revenue grew to $11.80B in 2025, and the stock trades at a P/E of 16.28. Recent news highlights YUMC's acquisition of Pizza Hut brand rights in mainland China and a $512 million share repurchase plan.
The outlook is positive given consistent earnings outperformance, strategic brand control expansion, and shareholder returns. Risks include China's competitive consumer market and economic sensitivity. Analyst consensus is strongly bullish with 14 buys and no sells, supporting a favorable investment case for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
